SCHEDULE 13G/A: PFM Health Sciences Group Discloses 6.5% Stake in Werewolf Therapeutics
Beneficial Ownership Report
PFM Health Sciences, LP and its affiliates have filed an amended Schedule 13G, revealing a continued beneficial ownership of 6.5% in Werewolf Therapeutics, Inc. as of December 31, 2024.
Summary
- PFM Health Sciences, LP, PFM Health Sciences GP, LLC, Partner Asset Management, LLC, and Brian D. Grossman (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G.
- The filing reports beneficial ownership of 2,905,465 shares of common stock in Werewolf Therapeutics, Inc.
- This aggregate amount represents 6.5% of Werewolf Therapeutics' common stock outstanding.
- The percentage is based on 44,563,153 shares outstanding as of November 1, 2024, as reported in the issuer's Form 10-Q filed on November 7, 2024.
- The Reporting Persons share both voting and dispositive power over all 2,905,465 shares.
- The shares are held by PFM Healthcare Master Fund, L.P. and PFM Biotech Opportunities LP (the "Funds"), for which PFM Health Sciences, LP acts as investment advisor.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Management Comments
- The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing indicates continued institutional investment in Werewolf Therapeutics, a biotechnology company. Such disclosures are standard for significant ownership stakes and provide transparency regarding major shareholders in the biotech sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in Werewolf Therapeutics, confirming a substantial long-term holding by PFM Health Sciences and its affiliates.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which Werewolf Therapeutics, Inc. reported 44,563,153 shares outstanding in its Form 10-Q. |
| 2024-11-07 | Date Werewolf Therapeutics, Inc. filed its Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 3. |
Keywords
Werewolf Therapeutics, PFM Health Sciences, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.